ML-7 HCl
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H530537

CAS#: 110448-33-4

Description: ML-7 is a MLCK inhibitor. ML-7 inhibits smooth muscle myosin light chain kinase (MLCK) with a Ki value of 0.3 µM. ML-7 amplifies the quinocetone-induced cell death through akt and MAPK-mediated apoptosis on HepG2 cell line. ML-7 inhibits exocytosis of superoxide-producing intracellular compartments in human neutrophils stimulated with phorbol myristate acetate in a myosin light chain kinase-independent manner.

Chemical Structure

img
ML-7 HCl
CAS# 110448-33-4
Instruction

Theoretical Analysis

Hodoodo Cat#: H530537
Name: ML-7 HCl
CAS#: 110448-33-4
Chemical Formula: C15H18ClIN2O2S
Exact Mass: 0.00
Molecular Weight: 452.736
Elemental Analysis: C, 39.79; H, 4.01; Cl, 7.83; I, 28.03; N, 6.19; O, 7.07; S, 7.08

Price and Availability

Size Price Availability Quantity
100mg USD 450 2 weeks
200mg USD 750 2 weeks
500mg USD 1250 2 weeks
1g USD 1950 2 weeks
2g USD 2950 2 weeks
5g USD 4250 2 weeks
Bulk inquiry

Synonym: ML-7 HCl; ML-7 hydrochloride; ML-7; ML 7; ML7.

IUPAC/Chemical Name: hexahydro-1-[(5-iodo-1-naphthalenyl)sulfonyl]-1H-1,4-diazepine, monohydrochloride

InChi Key: KDDALCDYHZIZMH-UHFFFAOYSA-N

InChi Code: InChI=1S/C15H17IN2O2S.ClH/c16-14-6-1-5-13-12(14)4-2-7-15(13)21(19,20)18-10-3-8-17-9-11-18;/h1-2,4-7,17H,3,8-11H2;1H

SMILES Code: O=S(N1CCNCCC1)(C2=C3C=CC=C(I)C3=CC=C2)=O.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 452.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Zhou Y, Zhang S, Deng S, Dai C, Tang S, Yang X, Li D, Zhao K, Xiao X. ML-7 amplifies the quinocetone-induced cell death through akt and MAPK-mediated apoptosis on HepG2 cell line. Toxicol Mech Methods. 2016;26(1):11-21. doi: 10.3109/15376516.2015.1090513. PubMed PMID: 26446980.

2: Cherlet M, Gleich S, Dewerchin H, Nauwynck H, Daminet S, De Backer P, Croubels S. Quantitative analysis of an anti-viral immune escape compound ML-7 in feline plasma using ultra performance liquid chromatography/electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Sep 15;905:118-26. doi: 10.1016/j.jchromb.2012.08.014. PubMed PMID: 22925719.

3: Lin HB, Cadete VJ, Sawicka J, Wozniak M, Sawicki G. Effect of the myosin light chain kinase inhibitor ML-7 on the proteome of hearts subjected to ischemia-reperfusion injury. J Proteomics. 2012 Sep 18;75(17):5386-95. doi: 10.1016/j.jprot.2012.06.016. PubMed PMID: 22749930.

4: Rosenthal R, Choritz L, Schlott S, Bechrakis NE, Jaroszewski J, Wiederholt M, Thieme H. Effects of ML-7 and Y-27632 on carbachol- and endothelin-1-induced contraction of bovine trabecular meshwork. Exp Eye Res. 2005 Jun;80(6):837-45. PubMed PMID: 15939040.

5: Odani K, Kobayashi T, Ogawa Y, Yoshida S, Seguchi H. ML-7 inhibits exocytosis of superoxide-producing intracellular compartments in human neutrophils stimulated with phorbol myristate acetate in a myosin light chain kinase-independent manner. Histochem Cell Biol. 2003 May;119(5):363-70. PubMed PMID: 12750906.

6: Kelley SJ, Thomas R, Dunham PB. Candidate inhibitor of the volume-sensitive kinase regulating K-Cl cotransport: the myosin light chain kinase inhibitor ML-7. J Membr Biol. 2000 Nov 1;178(1):31-41. PubMed PMID: 11058685.

7: Kozgunova E, Higashiyama T, Kurihara D. Cytokinesis defect in BY-2 cells caused by ATP-competitive kinase inhibitors. Plant Signal Behav. 2016 Oct 2;11(10):e1238547. PubMed PMID: 27662076; PubMed Central PMCID: PMC5257169.

8: Zhang Y, Li J, Chi Y, Li M, Pan X, Zhang Q, He X, Liu Y. [Myosin light chain kinase involved in change of intestinal mucosal barrier function in nonalcoholic steatohepatitis mice model]. Zhonghua Nei Ke Za Zhi. 2015 May;54(5):434-8. Chinese. PubMed PMID: 26080824.

9: Tian B, Brumback LC, Kaufman PL. ML-7, chelerythrine and phorbol ester increase outflow facility in the monkey Eye. Exp Eye Res. 2000 Dec;71(6):551-66. PubMed PMID: 11095907.

10: Shi W, Xu C, Hussain M, Wu F, Lu M, Wu X, Tang L, Wu X, Wu J. Inhibition of Myosin Light-Chain Kinase Enhances the Clearance of Lipopolysaccharide-Induced Lung Inflammation Possibly by Accelerating Neutrophil Apoptosis. Shock. 2017 Mar 7. doi: 10.1097/SHK.0000000000000863. [Epub ahead of print] PubMed PMID: 28272166.

11: Natarajan P, Crothers JM Jr, Rosen JE, Nakada SL, Rakholia M, Okamoto CT, Forte JG, Machen TE. Myosin IIB and F-actin control apical vacuolar morphology and histamine-induced trafficking of H-K-ATPase-containing tubulovesicles in gastric parietal cells. Am J Physiol Gastrointest Liver Physiol. 2014 Apr 15;306(8):G699-710. doi: 10.1152/ajpgi.00316.2013. PubMed PMID: 24578340; PubMed Central PMCID: PMC3989701.

12: Rossi JL, Todd T, Bazan NG, Belayev L. Inhibition of Myosin light-chain kinase attenuates cerebral edema after traumatic brain injury in postnatal mice. J Neurotrauma. 2013 Oct 1;30(19):1672-9. doi: 10.1089/neu.2013.2898. PubMed PMID: 23984869; PubMed Central PMCID: PMC3787387.

13: Bil-Lula I, Lin HB, Biały D, Wawrzyńska M, Diebel L, Sawicka J, Woźniak M, Sawicki G. Subthreshold nitric oxide synthase inhibition improves synergistic effects of subthreshold MMP-2/MLCK-mediated cardiomyocyte protection from hypoxic injury. J Cell Mol Med. 2016 Jun;20(6):1086-94. doi: 10.1111/jcmm.12827. PubMed PMID: 26992120; PubMed Central PMCID: PMC4882990.

14: Mackenzie AC, Kyle DD, McGinnis LA, Lee HJ, Aldana N, Robinson DN, Evans JP. Cortical mechanics and myosin-II abnormalities associated with post-ovulatory aging: implications for functional defects in aged eggs. Mol Hum Reprod. 2016 Jun;22(6):397-409. doi: 10.1093/molehr/gaw019. PubMed PMID: 26921397; PubMed Central PMCID: PMC4884917.

15: Wang B, Yan Y, Zhou J, Zhou Q, Gui S, Wang Y. A novel all-trans retinoid acid derivatives inhibits the migration of breast cancer cell lines MDA-MB-231 via myosin light chain kinase involving p38-MAPK pathway. Biomed Pharmacother. 2013 Jun;67(5):357-62. doi: 10.1016/j.biopha.2013.03.016. PubMed PMID: 23602051.

16: Eikemo H, Moltzau LR, Hussain RI, Nguyen CH, Qvigstad E, Levy FO, Skomedal T, Osnes JB. CaMKII in addition to MLCK contributes to phosphorylation of regulatory light chain in cardiomyocytes. Biochem Biophys Res Commun. 2016 Feb 26;471(1):219-25. doi: 10.1016/j.bbrc.2016.01.132. PubMed PMID: 26809094.

17: Droy-Lefaix MT, Bueno L, Caron P, Belot E, Roche O. Ocular inflammation and corneal permeability alteration by benzalkonium chloride in rats: a protective effect of a myosin light chain kinase inhibitor. Invest Ophthalmol Vis Sci. 2013 Apr 17;54(4):2705-10. doi: 10.1167/iovs.12-10193. PubMed PMID: 23518768; PubMed Central PMCID: PMC3632265.

18: Liu X, Xu J, Mei Q, Han L, Huang J. Myosin light chain kinase inhibitor inhibits dextran sulfate sodium-induced colitis in mice. Dig Dis Sci. 2013 Jan;58(1):107-14. doi: 10.1007/s10620-012-2304-3. PubMed PMID: 22777616.

19: Wu F, Guo X, Xu J, Wang W, Li B, Huang Q, Su L, Xu Q. Role of myosin light chain and myosin light chain kinase in advanced glycation end product-induced endothelial hyperpermeability in vitro and in vivo. Diab Vasc Dis Res. 2016 Mar;13(2):137-44. doi: 10.1177/1479164115610469. PubMed PMID: 26607798.

20: Nepiyushchikh ZV, Chakraborty S, Wang W, Davis MJ, Zawieja DC, Muthuchamy M. Differential effects of myosin light chain kinase inhibition on contractility, force development and myosin light chain 20 phosphorylation of rat cervical and thoracic duct lymphatics. J Physiol. 2011 Nov 15;589(Pt 22):5415-29. doi: 10.1113/jphysiol.2011.218446. PubMed PMID: 21930597; PubMed Central PMCID: PMC3240881.